Gliclazide

Gliclazide

Clinical data
ATC code	A10BB09 (WHO)
Identifiers
IUPAC name 3-(7-azabicyclo[3.3.0]oct-7-yl)- 1-(4-methylphenyl)sulfonyl-urea
CAS Number	21187-98-4
PubChem CID	3475
DrugBank	APRD00460
CompTox Dashboard (EPA)	DTXSID9023095
ECHA InfoCard	100.040.221
Chemical and physical data
Formula	C15H21N3O3S
Molar mass	323.412 g/mol g·mol−1

Gliclazide is an oral hypoglycemic (anti-diabetic drug) and is classified as a sulfonylurea. It is marketed as Diamicron MR®. DIAMICRON MR is also distributed as: Diabeton MR, Diamicron 30mg, Diamicron LM 30mg, Diamicron MR 30 mg, Diamicron Uno 30mg, Dianormax MR, Diaprel MR and Uni Diamicron.

• Official site

Form and Composition:

Each modified-release tablet contains 30 mg of gliclazide.

Not marketed in the United States.

Indication:

Type 2 diabetes.

Dosage:

30 to 120 mg depending on response, once daily with breakfast, including in elderly patients or those with mild-to-moderate renal failure

Properties:

Hypoglycemic sulfonylurea, restoring first peak of insulin secretion, increasing insulin sensitivity. Glycemia-independent hemovascular effects, antioxidant effect. No active circulating metabolites.

Contraindications:

type 1 diabetes, hypersensitivity to sulfonylureas, severe renal or hepatic failure, pregnancy and lactation, miconazole coprescription.

Interactions:

Hyperglycemic action may be caused by danazol, chlorpromazine, glucocorticoids, progestogens, ß-2 agonists. Its hypoglycemic action may be potentiated by phenylbutazone, alcohol, fluconazole, ß-blockers, possibly ACE inhibitors.

Adverse effects:

Hypoglycemia, gastrointestinal disturbance (reported), skin reactions (rare), hematological disorders (rare), hepatic enzyme rises (exceptional).

Overdosage:

Possible severe hypoglycemia requiring urgent IV glucose and monitoring.